Sensitization to olive pollen is a frequent cause of @entity7370 ( @entity7370 ) and @entity565 ( @entity565 ) in the region of Ja  n (southern Spain), where this allergen reaches atmospheric levels of almost 7000 grains/m3 during pollen season (May and June) and produces high morbidity. @entity6542 ( @entity6542 ) has proven very efficient in allergic @entity7370 and @entity565 caused by grass pollen. Considering the availability of a biologically standardized extract of @entity4135 , with its major allergen quantified in mass units, we decided to investigate @entity6542 with this extract in a group of rhinitic and/or @entity748 @entity1 monosensitized to olive. We studied tolerance, safety, and efficacy by comparison of the active group (subjected to @entity6542 ) with a control group that did not receive @entity6542 . A hyposensitizing dose of @entity4135 extract was administered preseasonally, establishing a maintenance dose 3.8 times higher than those administered in conventional treatments. Eighty-three percent of the @entity1 reached the proposed maximal dose of 75 BU, equivalent to 45 micrograms Ole e 1, with a rate of 0.8% of systemic reactions. A significant decrease in cutaneous (p < 0.001) and bronchial (p < 0.001) reactivity was observed in the active group, but not in the control group. Also, a decrease in specific IgE and an increase in IgG1 and IgG4 were found in the group of @entity1 treated with @entity6542 . Regarding clinical evolution, the active group, but not the control group, experienced a clear statistically significant improvement both in nasal (p < 0.05) and bronchial (p < 0.05) symptoms, in addition to a significant decrease in the consumption of antihistamines (p < 0.05) and beta 2-agonists (p < 0.01). In conclusion, @entity6542 with olive extract proved to be safe and efficacious for the treatment of @entity565 and @entity2490 caused by this allergen.

Immunotherapy with an extract of XXXX quantified in mass units. Evaluation of the safety and efficacy after one year of treatment.

@entity6542 :: ('MESH:C562465', 'Disease') :: ['Specific immunotherapy', 'SIT'] @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity7370 :: ('OMIM:613207', 'Disease') :: ['RC', 'rhinoconjunctivitis'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma', 'BA', 'bronchial asthma'] @entity4135 :: ('4146', 'Species') :: ['Olea europaea'] @entity2490 :: ('MESH:D012220', 'Disease') :: ['rhinitis']
@entity4135 :: (4146,Species) :: ['Olea europaea']
